The neoadjuvant chemotherapy setting is applied to some patients with locally advanced breast cancer to facilitate breast conservation during surgery and can provide important prognostic information about the response to treatment, particularly in HER2-positive breast cancer and TNBC [7]. This evidence concerns the gene ERBB2 and breast carcinoma.